Antibiotic Consumption 2017-2022 in 30 Private Hospitals in France: Impact of Antimicrobial Stewardship Tools and COVID-19 Pandemic

• Main Authors: Pierre-Marie Roger (Author), Diane Lesselingue (Author), Anouk Gérard (Author), Jacques Roghi (Author), Pauline Quint (Author), Sophie Un (Author), Agnès Chincholle (Author), Assi Assi (Author), Odile Bouchard (Author), Véronique Javaudin (Author), Eric Denes (Author)
• Format: Book
• Published: MDPI AG, 2024-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

Our aim was to determine the impact of antimicrobial stewardship tools (ASTs) and the COVID-19 pandemic on antibiotic consumption (AC). We used the national software Consores^® to determine AC in DDD/1000 days of hospitalization from 2017 to 2022 in voluntary private hospitals in France. The ASTs considered were: 1. internal guidelines; 2. the list of antibiotics with restricted access; 3. the presence of an antibiotic referent or 4. an ID specialist; and 5. proof of an annual meeting on antimicrobial resistance. Institutions with dedicated units for COVID-19 patients were specified. In 30 institutions, the total AC varied from (means) 390 to 405 DDD/1000 DH from 2017 to 2022. Fluoroquinolones and amoxicillin/clavulanate consumption decreased from 50 to 36 (<i>p</i> = 0.003) and from 112 to 77 (<i>p</i> = 0.025), respectively, but consumption of piperacillin/tazobactam increased from 9 to 21 (<i>p</i> < 0.001). Over the study period, 10 institutions with ≤2 AST had lower AC compared to 20 institutions with ≥3 AST (<i>p</i> < 0.01). COVID-19 units opened in 10 institutions were associated with a trend toward higher macrolide consumption from 15 to 25 from 2017 to 2020 (<i>p</i> = 0.065) and with an acceleration of piperacillin/tazobactam consumption from 2020 to 2022 (<i>p</i> ≤ 0.003). Antibiotic consumption in 30 private hospitals in France was inversely related to the number of AST. The COVID-19 pandemic was associated with limited impact on AC, but special attention should be paid to piperacillin/tazobactam consumption.

Item Description

10.3390/antibiotics13020180
2079-6382